Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose-escalating trial

Introduction Osteogenesis imperfecta (OI) is the most common inherited cause of bone fragility (approximately 1 in 16 000). People with OI suffer bone fragility causing fractures, pain and deformity; sarcopenia causing fatigue and poor endurance; aortic root dilatation and hearing loss. No drug curr...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Judith Cohen, Chao Huang, Nick Bishop, Bronwen Williams, Laura Simms, Mahboobeh Haji Sadeghi, Amy Wilkinson, Sarah Sumpter, Keith Pugh, Charlotte Heath, Luca Sangiorgi, Francesca Gurioli, Maria Gnoli, Alice Moroni, Martina Piccinni Leopardi, Clara Del Coco
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2025-12-01
Edice:	BMJ Open
On-line přístup:	https://bmjopen.bmj.com/content/15/12/e107243.full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!